Acumen Pharmaceuticals (ABOS) Research & Development (2020 - 2026)

Acumen Pharmaceuticals has disclosed Research & Development across 7 years of filings, most recently posting $27.8 million for Q2 2026.

• In Q2 2026, Research & Development fell 25.09% year-over-year to $27.8 million; the TTM figure through Jun 2026 stood at $86.8 million (down 30.13% YoY), while the FY2025 annual figure was $104.9 million, up 11.82% from the prior year.
• Research & Development came in at $27.8 million for Q2 2026 at Acumen Pharmaceuticals, up from $16.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $37.1 million in Q2 2025 to a low of $6.0 million in Q1 2022.
• Average Research & Development over 5 years is $17.6 million, with a median of $14.9 million recorded in 2023.
• Year-over-year, Research & Development soared 361.61% in 2022 and plunged 40.62% in 2025.
• Over 5 years, Research & Development stood at $10.7 million in 2022, then climbed by 23.7% to $13.3 million in 2023, then surged by 160.05% to $34.6 million in 2024, then sank by 40.62% to $20.5 million in 2025, then jumped by 35.48% to $27.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $27.8 million in Q2 2026, $16.5 million in Q1 2026, and $20.5 million in Q4 2025.